Results 111 to 120 of about 6,610 (157)
A Multifactorial Case of Acquired Hemophilia A. [PDF]
CureusWillis JP, Kanne T, Cole A, Nelson G.
europepmc +1 more source
Dental surgery for patients with bleeding disorder of unknown cause. [PDF]
Br Dent JKhan I.
europepmc +1 more source
Repeated hemorrhagic ulcers of the esophagus associated with acquired hemophilia A: A case report. [PDF]
World J Gastrointest EndoscSaito M +8 more
europepmc +1 more source
Hemostatic rescue with rFVIIa in Bernard-Soulier syndrome refractory to HLA-matched platelet transfusion. [PDF]
Ann HematolOkamoto Y +6 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
The Judicious Use of Recombinant Factor VIIa
Seminars in Thrombosis and Hemostasis, 2016Recombinant activated factor VIIa (rFVIIa) is a prohemostatic agent initially approved for use in hemophilia patients with inhibitors and recently for Glanzmann thrombasthenia. Despite its approval indications, rFVIIa has also been used for a diverse range of off-label indications to treat bleeding related to traumatic injury, major hemorrhage ...
Jerrold H Levy, Lawrence Tim Goodnough
exaly +3 more sources
BioDrugs, 1999
Recombinant factor VIIa is a preparation of activated coagulation factor VII (factor VIIa) that is produced by recombinant DNA technology. The drug expedites blood coagulation without the need for factors VIII and IX in patients with haemophilia. Indicators of activation of systemic coagulation of blood were unchanged and mean prothrombin times and ...
C J, Dunn, C M, Spencer
+7 more sources
Recombinant factor VIIa is a preparation of activated coagulation factor VII (factor VIIa) that is produced by recombinant DNA technology. The drug expedites blood coagulation without the need for factors VIII and IX in patients with haemophilia. Indicators of activation of systemic coagulation of blood were unchanged and mean prothrombin times and ...
C J, Dunn, C M, Spencer
+7 more sources
Emergency Medicine, 2004
Human coagulation factor (F) VII is a single chain protease that circulates in the blood as a weakly active zymogen at concentrations of approximately 10 nmol/L. When converted to the active 2 chain form (FVIIa), it is a powerful initiator of haemostasis. Recombinant factor VIIa (rFVIIa, eptacog alfa, NovoSeven) is a genetically engineered product that
openaire +2 more sources
Human coagulation factor (F) VII is a single chain protease that circulates in the blood as a weakly active zymogen at concentrations of approximately 10 nmol/L. When converted to the active 2 chain form (FVIIa), it is a powerful initiator of haemostasis. Recombinant factor VIIa (rFVIIa, eptacog alfa, NovoSeven) is a genetically engineered product that
openaire +2 more sources
Thrombosis and Haemostasis, 2005
SummaryRecombinant activated factor VII (rFVIIa, Novo Seven®) has been successfully used to treat bleeding episodes in patients with antibodies against coagulation factors VIII and IX. In recent years, rFVIIa has also been employed for the management of uncontrolled bleeding in a number of congenital and acquired haemos- tatic abnormalities. Based on a
Per Rexen +4 more
openaire +4 more sources
SummaryRecombinant activated factor VII (rFVIIa, Novo Seven®) has been successfully used to treat bleeding episodes in patients with antibodies against coagulation factors VIII and IX. In recent years, rFVIIa has also been employed for the management of uncontrolled bleeding in a number of congenital and acquired haemos- tatic abnormalities. Based on a
Per Rexen +4 more
openaire +4 more sources